EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives

Christina Hart, Nick van Es, Minna Voigtlaender

Hämostaseologie · 01.04.2025 · 45 (02) · 127-138

DOI: 10.1055/a-2374-3425 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.04.2025. Verfasst von Christina Hart und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Neoplasms, Thrombosis, Anticoagulants, Primary Prevention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past two decades, the incidence of cancer-associated thrombosis (CAT) has increased. It is nowadays a common and often serious complication among patients with cancer. Although medical thromboprophylaxis is recommended for most surgical and nonsurgical cancer patients, it has been infrequently used in ambulatory patients with cancer because of the burden of treatment and concerns about bleeding. However, various risk assessment scores are now available and randomized placebo-controlled trials have established the efficacy of low-molecular-weight heparin or the direct oral Xa inhibitors rivaroxaban and apixaban in ambulatory patients with cancer at high risk of venous thromboembolism (VTE). This review provides an overview of (1) primary thromboprophylaxis in the setting of hospitalized surgical and medical patients, (2) extended thromboprophylaxis after hospital discharge, (3) performance of risk assessment tools for CAT, and (4) primary thromboprophylaxis in ambulatory patients with cancer. The aim is to provide support to physicians in identifying ambulatory patients with cancer at high VTE risk who benefit most from medical thromboprophylaxis according to current recommendations from international guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsThrombosisAnticoagulantsPrimary PreventionHumansRisk FactorsHeparin, Low-Molecular-Weight

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Department of Vascular Medicine, Amsterdam UMC location, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, The Netherlands.
  • Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Zitieren

APA

Hart, C., van Es, N., & Voigtlaender, M. (2025). Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives. Hämostaseologie, 45(02), 127-138. https://doi.org/10.1055/a-2374-3425

Vancouver

Hart C, van Es N, Voigtlaender M. Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives. Hämostaseologie. 2025;45(02):127-138. doi:10.1055/a-2374-3425

BibTeX
@article{Hart2025,
  author = {Hart, Christina and van Es, Nick and Voigtlaender, Minna},
  title = {Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives},
  journal = {Hämostaseologie},
  year = {2025},
  volume = {45},
  number = {02},
  pages = {127--138},
  doi = {10.1055/a-2374-3425}
}
Kostenlos starten →